Merck to Acquire Terns Pharmaceuticals for $53.00/Share, Valuing Company at $6.7 Billion

summarizeSummary

Terns Pharmaceuticals has entered into a definitive merger agreement to be acquired by Merck for $53.00 per share in cash, representing a substantial premium and an equity value of approximately $6.7 billion. This acquisition will integrate Terns' lead candidate, TERN-701, into Merck's hematology pipeline.

check_boxKey Events

• Acquisition Agreement Signed

  Terns Pharmaceuticals has entered into a definitive merger agreement to be acquired by Merck Sharp & Dohme LLC.

• Offer Price and Valuation

  Merck will acquire all outstanding shares of Terns for $53.00 per share in cash, representing an approximate equity value of $6.7 billion ($5.7 billion net of acquired cash). This price reflects a significant premium over recent trading averages.

• Strategic Asset Integration

  The acquisition is centered on Terns' lead candidate, TERN-701, a novel oral allosteric BCR::ABL1 tyrosine kinase inhibitor for chronic myeloid leukemia (CML), which will expand Merck's hematology pipeline.

• Transaction Structure and Timeline

  The acquisition will proceed via a tender offer, subject to customary conditions including shareholder tender and HSR Act clearance, with an expected closing in the second quarter of 2026.

auto_awesomeAnalysis

This 8-K filing announces a definitive agreement for Merck to acquire Terns Pharmaceuticals, Inc. for $53.00 per share in cash. This offer price represents a significant premium over recent trading prices, including a 31% premium to the 60-day volume-weighted average stock price and a 42% premium to the 90-day volume-weighted average stock price as of March 24, 2026. The total equity value of the transaction is approximately $6.7 billion, or $5.7 billion net of acquired cash. The acquisition is strategically driven by Terns' lead candidate, TERN-701, an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor for chronic myeloid leukemia (CML), which Merck aims to integrate into its growing hematology pipeline. The transaction is structured as a tender offer, subject to a majority of Terns' stockholders tendering their shares and regulatory approvals, including the expiration of the HSR Act waiting period. The deal is expected to close in the second quarter of 2026. This is a highly positive event for Terns shareholders, offering immediate and substantial value.